{"entity":{"id":"nct07228247","kind":"trial","name":"A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of HMPL-A251 in advanced solid tumours, run by Hutchmed, now recruiting.","summary":"A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors is a phase 1/2 interventional study registered as NCT07228247 by Hutchmed, with 147 participants planned, started 2025-12-16 and due to reach its primary completion in 2028-11-30. Interventions recorded: HMPL-A251.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07228247","url":"https://clinicaltrials.gov/study/NCT07228247"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["hutchmed"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07228247","phase":"1/2","setting":"A Phase Ⅰ/Ⅱa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HMPL-A251 in Participants With Advanced or Metastatic HER2-Expressing Solid Tumors","sponsor":"Hutchmed","enrolled":147,"outcomes":[]},"route":"/trials/nct07228247/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"hutchmed","kind":"company","name":"Hutchmed","route":"/companies/hutchmed/"}]}}